methoxyetomidate

Methoxyetomidate is a synthetic analog of etomidate designed as an intravenous anesthetic agent. It is a small molecule that acts primarily as a positive allosteric modulator and agonist at gamma-aminobutyric acid type A (GABA-A) receptors, similar to etomidate. Methoxyetomidate was developed to retain the rapid onset and short duration of anesthesia seen with etomidate but with reduced risk of adrenal suppression—a significant adverse effect associated with etomidate due to inhibition of 11β-hydroxylase in the adrenal cortex. Preclinical studies suggest that methoxyetomidate provides effective anesthesia while minimizing suppression of cortisol synthesis, making it potentially safer for use in critically ill patients or those requiring repeated dosing.

Other names

MOC-etomidatemethoxycarbonyl-etomidate